FOLH1 and prostate carcinoma: The therapeutic efficacy of this approach for CNS tumors is hitherto only shown in patients with cerebral metastasis from prostate cancer that were treated with the anti-PSMA-based radiopharmaceuticals [177Lu]Lu-PSMA-617 and [225Ac]Ac-PSMA-617 [126,127,128].